Skip to Content

Estropipate Pregnancy and Breastfeeding Warnings

Estropipate is also known as: Ogen, Ogen 0.625, Ogen 1.25, Ogen 2.5, Ortho-Est

Medically reviewed on December 18, 2017

Estropipate Pregnancy Warnings

Estropipate has been assigned to FDA pregnancy category X. There is no indication for the use of estrogens during pregnancy. Estropipate is contraindicated for use during pregnancy. Estrogenic agents have been associated with urogenital abnormalities in offspring that manifest later in life. Vaginal adenosis, squamous cell dysplasia of the uterine cervix and vaginal cancer have developed later in life in female offspring. In the male offspring, the risks of urogenital abnormalities and testicular cancer later in life are increased.

See references

Estropipate Breastfeeding Warnings

There are no data on the excretion of estropipate into human milk. Other estrogens are distributed into breast milk. Estrogens administered to nursing women have been shown to decrease the quantity and quality of breast milk.

See references

References for pregnancy information

  1. "Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical, Raritan, NJ.
  2. Heinonen O, Slone D, Shapiro S; Kaufman DW ed. "Birth Defects and Drugs in Pregnancy." Littleton, MA: Publishing Sciences Group, Inc. (1977): 297

References for breastfeeding information

  1. "Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical, Raritan, NJ.
  2. Committee on Drugs, 1992 to 1993 "The transfer of drugs and other chemicals into human milk." Pediatrics 93 (1994): 137-50

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide